Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial

What Was Tested

This randomized controlled trial paper looks at Abaloparatide and Teriparatide.

Who Took Part

The abstract describes 222 women taking part.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, women only.

TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.

Assessments were made at baseline, 12 and 24 weeks.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The women were allocated by chance, so the Abaloparatide group and the comparison group should start out alike.

As a double-blind Abaloparatide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Abaloparatide could be set against what happens without it.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Cancellous Bone, Lumbar Vertebrae, Osteoporosis, Postmenopausal and Osteoporotic Fractures.

The authors tagged it with the keywords Anabolics, Bone microarchitecture and Clinical trials.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Abaloparatide and Teriparatide in 222 women.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Abaloparatide compound page and the Teriparatide compound page, all human trials.